Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California. more
Time Frame | RARE | Sector | S&P500 |
---|---|---|---|
1-Week Return | -7.29% | -3.35% | -2.97% |
1-Month Return | -3.68% | -3.49% | -0.66% |
3-Month Return | -26.05% | -12.6% | 2.71% |
6-Month Return | 14.33% | -6.91% | 7.21% |
1-Year Return | -9.83% | 1.19% | 23.04% |
3-Year Return | -50.32% | -0.21% | 28.43% |
5-Year Return | -0.21% | 33.09% | 82.88% |
10-Year Return | -10.15% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 103.71M | 271.03M | 351.41M | 363.33M | 434.25M | [{"date":"2019-12-31","value":23.88,"profit":true},{"date":"2020-12-31","value":62.41,"profit":true},{"date":"2021-12-31","value":80.92,"profit":true},{"date":"2022-12-31","value":83.67,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 9.01M | 6.13M | 16.01M | 28.32M | 45.21M | [{"date":"2019-12-31","value":19.93,"profit":true},{"date":"2020-12-31","value":13.56,"profit":true},{"date":"2021-12-31","value":35.41,"profit":true},{"date":"2022-12-31","value":62.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | 94.71M | 264.90M | 335.40M | 335.01M | 389.04M | [{"date":"2019-12-31","value":24.34,"profit":true},{"date":"2020-12-31","value":68.09,"profit":true},{"date":"2021-12-31","value":86.21,"profit":true},{"date":"2022-12-31","value":86.11,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | 91.31% | 97.74% | 95.44% | 92.21% | 89.59% | [{"date":"2019-12-31","value":93.43,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":97.65,"profit":true},{"date":"2022-12-31","value":94.34,"profit":true},{"date":"2023-12-31","value":91.66,"profit":true}] |
Operating Expenses | 518.88M | 595.02M | 717.13M | 983.93M | 958.25M | [{"date":"2019-12-31","value":52.74,"profit":true},{"date":"2020-12-31","value":60.47,"profit":true},{"date":"2021-12-31","value":72.88,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":97.39,"profit":true}] |
Operating Income | (424.17M) | (330.12M) | (381.74M) | (648.92M) | (569.21M) | [{"date":"2019-12-31","value":-42417300000,"profit":false},{"date":"2020-12-31","value":-33011600000,"profit":false},{"date":"2021-12-31","value":-38173700000,"profit":false},{"date":"2022-12-31","value":-64891900000,"profit":false},{"date":"2023-12-31","value":-56920800000,"profit":false}] |
Total Non-Operating Income/Expense | 36.83M | 118.50M | (100.67M) | (84.75M) | (78.57M) | [{"date":"2019-12-31","value":31.08,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-84.95,"profit":false},{"date":"2022-12-31","value":-71.51,"profit":false},{"date":"2023-12-31","value":-66.3,"profit":false}] |
Pre-Tax Income | (399.44M) | (185.36M) | (452.98M) | (701.73M) | (608.46M) | [{"date":"2019-12-31","value":-39944400000,"profit":false},{"date":"2020-12-31","value":-18535900000,"profit":false},{"date":"2021-12-31","value":-45298100000,"profit":false},{"date":"2022-12-31","value":-70172500000,"profit":false},{"date":"2023-12-31","value":-60846400000,"profit":false}] |
Income Taxes | 3.28M | 1.21M | 1.04M | 5.70M | (1.82M) | [{"date":"2019-12-31","value":57.64,"profit":true},{"date":"2020-12-31","value":21.19,"profit":true},{"date":"2021-12-31","value":18.33,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-32.04,"profit":false}] |
Income After Taxes | (402.73M) | (186.57M) | (454.02M) | (707.42M) | (606.64M) | [{"date":"2019-12-31","value":-40272700000,"profit":false},{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false}] |
Income From Continuous Operations | (402.73M) | (186.57M) | (454.02M) | (707.42M) | (606.64M) | [{"date":"2019-12-31","value":-40272700000,"profit":false},{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (402.73M) | (186.57M) | (454.02M) | (707.42M) | (606.64M) | [{"date":"2019-12-31","value":-40272700000,"profit":false},{"date":"2020-12-31","value":-18656600000,"profit":false},{"date":"2021-12-31","value":-45402500000,"profit":false},{"date":"2022-12-31","value":-70742100000,"profit":false},{"date":"2023-12-31","value":-60663900000,"profit":false}] |
EPS (Diluted) | (7.29) | (3.00) | (6.71) | (10.11) | (8.33) | [{"date":"2019-12-31","value":-729,"profit":false},{"date":"2020-12-31","value":-300,"profit":false},{"date":"2021-12-31","value":-671,"profit":false},{"date":"2022-12-31","value":-1011,"profit":false},{"date":"2023-12-31","value":-833,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
RARE | |
---|---|
Cash Ratio | 2.18 |
Current Ratio | 2.81 |
Quick Ratio | 2.65 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
RARE | |
---|---|
ROA (LTM) | -24.12% |
ROE (LTM) | -289.98% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
RARE | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.77 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.23 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
RARE | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 7.59 |
P/B | 11.45 |
Price/FCF | NM |
EV/R | 6.47 |
EV/Ebitda | NM |
PEG | NM |
Ultragenyx (RARE) share price today is $43.47
Yes, Indians can buy shares of Ultragenyx (RARE) on Vested. To buy Ultragenyx from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in RARE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ultragenyx (RARE) via the Vested app. You can start investing in Ultragenyx (RARE) with a minimum investment of $1.
You can invest in shares of Ultragenyx (RARE) via Vested in three simple steps:
The 52-week high price of Ultragenyx (RARE) is $60.37. The 52-week low price of Ultragenyx (RARE) is $37.02.
The price-to-earnings (P/E) ratio of Ultragenyx (RARE) is
The price-to-book (P/B) ratio of Ultragenyx (RARE) is 11.45
The dividend yield of Ultragenyx (RARE) is 0.00%
The market capitalization of Ultragenyx (RARE) is $3.97B
The stock symbol (or ticker) of Ultragenyx is RARE